Postoperative pain in lung cancer patients
Conditions
Interventions
Low dose dexmedetomidine combined with hydromorphone group (D1 group):Analgesic pump drug: Dexmedetomidine 1 µ g/kg+hydromorphone 50 µ g/kg diluted to 100ml with normal saline
Medium dose dexmedetomidine combined with hydromorphone group (D2 group):Analgesic pump drug: Dexmedetomidine 1.5 µ g/kg+hydromorphone 50 µ g/kg diluted to 100ml with normal saline
High dose dexmedetomidine combined with hydromorphone group (D3 group):Analgesic pump drug: Dexmedetomidine 2 µ g/kg+hydromorphone 50 µ g/kg diluted to 100ml with normal saline
Hydromorphone group (H group):Analgesic pump drug: hydromorphone 50 µ g/kg diluted to 100ml with normal saline
Sponsors
Shifang people's Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. ASA ? - ?; 2. The age ranged from 20 to 80 years; 3. Body weight 45-80 kg; 4. Ethical and informed consent.
Exclusion criteria
Exclusion criteria: 1. Preoperative opioid addiction; 2. Mental and nervous system diseases; 3. History of asthma; 4. Severe cardiopulmonary dysfunction and liver and kidney dysfunction; 5. Patients who refused to cooperate with the trial; 6. Skin lesions at the puncture site, history of severe vomiting or motion sickness, and communication difficulties.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score; Ramsay sedmion scale ,RSS score;TNF-a;IL-10;IL-6;HMGBl;Number of compressions for self controlled pain relief; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate;Mean arterial pressure;Postoperative adverse reactions such as nausea, vomiting, dizziness, and respiratory depression; | — |
Countries
China
Contacts
Public ContactLin Zeng
Shifang people's Hospital
Outcome results
None listed